Statera Biopharma, Inc. announced the resignation of Peter Aronstam as Chief Financial Officer, effective from May 27, 2022. The Board of Directors of the Company has commenced a search for a new Chief Financial Officer.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0006 USD | 0.00% |
|
0.00% | 0.00% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 43.55K | |
+23.13% | 46.93B | |
+37.12% | 39.08B | |
-8.73% | 38.48B | |
+28.09% | 31.01B | |
-12.26% | 26.14B | |
+10.57% | 25.88B | |
+45.05% | 14.15B | |
+32.23% | 12.53B | |
-6.56% | 11.36B |
- Stock Market
- Equities
- STAB Stock
- News Statera Biopharma, Inc.
- Statera Biopharma, Inc. Announces Resignation of Peter Aronstam as Chief Financial Officer